BR112023018826A2 - Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos - Google Patents

Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Info

Publication number
BR112023018826A2
BR112023018826A2 BR112023018826A BR112023018826A BR112023018826A2 BR 112023018826 A2 BR112023018826 A2 BR 112023018826A2 BR 112023018826 A BR112023018826 A BR 112023018826A BR 112023018826 A BR112023018826 A BR 112023018826A BR 112023018826 A2 BR112023018826 A2 BR 112023018826A2
Authority
BR
Brazil
Prior art keywords
c5ar1
treatment
taxanes
inhibitors
hypersensitivity reactions
Prior art date
Application number
BR112023018826A
Other languages
English (en)
Inventor
Andrea Aramini
Anna Sirico
Laura Brandolini
Marcello Allegretti
Candida Cesta Maria
Piergiorgio Amendola
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of BR112023018826A2 publication Critical patent/BR112023018826A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos. a presente invenção refere-se ao uso de um inibidor de c5ar1 para a prevenção ou tratamento de uma reação de hipersensibilidade (rhs) a um taxano em um indivíduo.
BR112023018826A 2021-03-17 2022-03-17 Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos BR112023018826A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
BR112023018826A2 true BR112023018826A2 (pt) 2024-03-12

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018826A BR112023018826A2 (pt) 2021-03-17 2022-03-17 Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Country Status (7)

Country Link
US (1) US20240180888A1 (pt)
EP (1) EP4308114A1 (pt)
JP (1) JP2024512472A (pt)
BR (1) BR112023018826A2 (pt)
CA (1) CA3212816A1 (pt)
IL (1) IL305727A (pt)
WO (1) WO2022195017A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ9904244A3 (cs) * 1997-05-27 2001-10-17 Baker Norton Pharmaceuticals, Inc. Pouľití taxanů, jejich derivátů, analogů nebo předléků pro přípravu farmaceutického prostředku pro perorální podávání
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
JP5374157B2 (ja) 2005-11-24 2013-12-25 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
IL305727A (en) 2023-11-01
EP4308114A1 (en) 2024-01-24
WO2022195017A1 (en) 2022-09-22
CA3212816A1 (en) 2022-09-22
US20240180888A1 (en) 2024-06-06
JP2024512472A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
CY1124483T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστικοτητας της αργινασης
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
CO2017013234A2 (es) Mezcla para tratar fertilizantes que contienen urea
MX2021002865A (es) Derivados de tiocarbamato como inhibidores de a2a, composición farmacéutica de los mismos y combinaciones con agentes antineoplásicos.
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CO6751239A2 (es) Compuesto bicíclico
BR112015004968A2 (pt) combinações de compostos ativos
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
ECSP14004595A (es) 2-tiopirimidinonas
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
BR112023025869A2 (pt) Derivados de quinazolina úteis como inibidores de ras
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
UA108102C2 (uk) Біциклічні похідні і їх застосування як інгібіторів асс
BR112014018670A8 (pt) Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
BR112023018619A2 (pt) Inibidores de heteroaril de calicreína plasmática
BR112018072740A2 (pt) realçador de inibidores de homólogo 2 de zeste
CO2022000270A2 (es) Inhibidores de enzimas
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
BR112023018826A2 (pt) Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos